Global Single Dose Dry Powder Inhaler Device 麻豆原创 Research Report 2025

Publication ID:

PB502256052

Publication Date:

February 25, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Medical Devices [2]

Pharma & Healthcare [3]

Description:

The global market for Single Dose Dry Powder Inhaler Device was valued at US$ 241 million in the year 2024 and is projected to reach a revised size of US$ 332 million by 2031, growing at a CAGR of 4.6% during the forecast period.
A Single-Dose Dry Powder Inhaler (DPI) device is a type of inhalation device designed to deliver a single, pre-measured dose of dry powder medication directly into the lungs. The device typically uses either a capsule or blister containing the medication. Each dose is delivered individually, and the device is emptied after use. To take a dose, the patient inhales through the device, which generates airflow to carry the dry powder into the lungs.
North American market for Single Dose Dry Powder Inhaler Device is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Single Dose Dry Powder Inhaler Device is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Single Dose Dry Powder Inhaler Device include Hovione, GlaxoSmithKline, AstraZeneca, Novartis, 3M, Chiesi, Teva, Vectura, Mannkind, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Single Dose Dry Powder Inhaler Device, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Single Dose Dry Powder Inhaler Device.
The Single Dose Dry Powder Inhaler Device market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Single Dose Dry Powder Inhaler Device market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Single Dose Dry Powder Inhaler Device manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Hovione
GlaxoSmithKline
AstraZeneca
Novartis
3M
Chiesi
Teva
Vectura
Mannkind
Segment by Type
Capsule-based
Blister-based
Segment by Application
Asthma
COPD
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Single Dose Dry Powder Inhaler Device manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Single Dose Dry Powder Inhaler Device in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Single Dose Dry Powder Inhaler Device 麻豆原创 Overview
1.1 Product Definition
1.2 Single Dose Dry Powder Inhaler Device by Type
1.2.1 Global Single Dose Dry Powder Inhaler Device 麻豆原创 Value Comparison by Type (2024 VS 2031)
1.2.2 Capsule-based
1.2.3 Blister-based
1.3 Single Dose Dry Powder Inhaler Device by Application
1.3.1 Global Single Dose Dry Powder Inhaler Device 麻豆原创 Value by Application (2024 VS 2031)
1.3.2 Asthma
1.3.3 COPD
1.3.4 Others
1.4 Global Single Dose Dry Powder Inhaler Device 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Single Dose Dry Powder Inhaler Device Revenue 2020-2031
1.4.2 Global Single Dose Dry Powder Inhaler Device Sales 2020-2031
1.4.3 Global Single Dose Dry Powder Inhaler Device 麻豆原创 Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Single Dose Dry Powder Inhaler Device 麻豆原创 Competition by Manufacturers
2.1 Global Single Dose Dry Powder Inhaler Device Sales 麻豆原创 Share by Manufacturers (2020-2025)
2.2 Global Single Dose Dry Powder Inhaler Device Revenue 麻豆原创 Share by Manufacturers (2020-2025)
2.3 Global Single Dose Dry Powder Inhaler Device Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Single Dose Dry Powder Inhaler Device, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Single Dose Dry Powder Inhaler Device, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Single Dose Dry Powder Inhaler Device, Product Type & Application
2.7 Global Key Manufacturers of Single Dose Dry Powder Inhaler Device, Date of Enter into This Industry
2.8 Global Single Dose Dry Powder Inhaler Device 麻豆原创 Competitive Situation and Trends
2.8.1 Global Single Dose Dry Powder Inhaler Device 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest Single Dose Dry Powder Inhaler Device Players 麻豆原创 Share by Revenue
2.8.3 Global Single Dose Dry Powder Inhaler Device Company Type and 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Single Dose Dry Powder Inhaler Device 麻豆原创 Scenario by Region
3.1 Global Single Dose Dry Powder Inhaler Device 麻豆原创 Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Single Dose Dry Powder Inhaler Device Sales by Region: 2020-2031
3.2.1 Global Single Dose Dry Powder Inhaler Device Sales by Region: 2020-2025
3.2.2 Global Single Dose Dry Powder Inhaler Device Sales by Region: 2026-2031
3.3 Global Single Dose Dry Powder Inhaler Device Revenue by Region: 2020-2031
3.3.1 Global Single Dose Dry Powder Inhaler Device Revenue by Region: 2020-2025
3.3.2 Global Single Dose Dry Powder Inhaler Device Revenue by Region: 2026-2031
3.4 North America Single Dose Dry Powder Inhaler Device 麻豆原创 Facts & Figures by Country
3.4.1 North America Single Dose Dry Powder Inhaler Device 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Single Dose Dry Powder Inhaler Device Sales by Country (2020-2031)
3.4.3 North America Single Dose Dry Powder Inhaler Device Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Single Dose Dry Powder Inhaler Device 麻豆原创 Facts & Figures by Country
3.5.1 Europe Single Dose Dry Powder Inhaler Device 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Single Dose Dry Powder Inhaler Device Sales by Country (2020-2031)
3.5.3 Europe Single Dose Dry Powder Inhaler Device Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Single Dose Dry Powder Inhaler Device 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific Single Dose Dry Powder Inhaler Device 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Single Dose Dry Powder Inhaler Device Sales by Region (2020-2031)
3.6.3 Asia Pacific Single Dose Dry Powder Inhaler Device Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Single Dose Dry Powder Inhaler Device 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Single Dose Dry Powder Inhaler Device 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Single Dose Dry Powder Inhaler Device Sales by Country (2020-2031)
3.7.3 Latin America Single Dose Dry Powder Inhaler Device Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Single Dose Dry Powder Inhaler Device 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Single Dose Dry Powder Inhaler Device 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Single Dose Dry Powder Inhaler Device Sales by Country (2020-2031)
3.8.3 Middle East and Africa Single Dose Dry Powder Inhaler Device Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Single Dose Dry Powder Inhaler Device Sales by Type (2020-2031)
4.1.1 Global Single Dose Dry Powder Inhaler Device Sales by Type (2020-2025)
4.1.2 Global Single Dose Dry Powder Inhaler Device Sales by Type (2026-2031)
4.1.3 Global Single Dose Dry Powder Inhaler Device Sales 麻豆原创 Share by Type (2020-2031)
4.2 Global Single Dose Dry Powder Inhaler Device Revenue by Type (2020-2031)
4.2.1 Global Single Dose Dry Powder Inhaler Device Revenue by Type (2020-2025)
4.2.2 Global Single Dose Dry Powder Inhaler Device Revenue by Type (2026-2031)
4.2.3 Global Single Dose Dry Powder Inhaler Device Revenue 麻豆原创 Share by Type (2020-2031)
4.3 Global Single Dose Dry Powder Inhaler Device Price by Type (2020-2031)
5 Segment by Application
5.1 Global Single Dose Dry Powder Inhaler Device Sales by Application (2020-2031)
5.1.1 Global Single Dose Dry Powder Inhaler Device Sales by Application (2020-2025)
5.1.2 Global Single Dose Dry Powder Inhaler Device Sales by Application (2026-2031)
5.1.3 Global Single Dose Dry Powder Inhaler Device Sales 麻豆原创 Share by Application (2020-2031)
5.2 Global Single Dose Dry Powder Inhaler Device Revenue by Application (2020-2031)
5.2.1 Global Single Dose Dry Powder Inhaler Device Revenue by Application (2020-2025)
5.2.2 Global Single Dose Dry Powder Inhaler Device Revenue by Application (2026-2031)
5.2.3 Global Single Dose Dry Powder Inhaler Device Revenue 麻豆原创 Share by Application (2020-2031)
5.3 Global Single Dose Dry Powder Inhaler Device Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Hovione
6.1.1 Hovione Company Information
6.1.2 Hovione Description and Business Overview
6.1.3 Hovione Single Dose Dry Powder Inhaler Device Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Hovione Single Dose Dry Powder Inhaler Device Product Portfolio
6.1.5 Hovione Recent Developments/Updates
6.2 GlaxoSmithKline
6.2.1 GlaxoSmithKline Company Information
6.2.2 GlaxoSmithKline Description and Business Overview
6.2.3 GlaxoSmithKline Single Dose Dry Powder Inhaler Device Sales, Revenue and Gross Margin (2020-2025)
6.2.4 GlaxoSmithKline Single Dose Dry Powder Inhaler Device Product Portfolio
6.2.5 GlaxoSmithKline Recent Developments/Updates
6.3 AstraZeneca
6.3.1 AstraZeneca Company Information
6.3.2 AstraZeneca Description and Business Overview
6.3.3 AstraZeneca Single Dose Dry Powder Inhaler Device Sales, Revenue and Gross Margin (2020-2025)
6.3.4 AstraZeneca Single Dose Dry Powder Inhaler Device Product Portfolio
6.3.5 AstraZeneca Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Company Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Single Dose Dry Powder Inhaler Device Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Novartis Single Dose Dry Powder Inhaler Device Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 3M
6.5.1 3M Company Information
6.5.2 3M Description and Business Overview
6.5.3 3M Single Dose Dry Powder Inhaler Device Sales, Revenue and Gross Margin (2020-2025)
6.5.4 3M Single Dose Dry Powder Inhaler Device Product Portfolio
6.5.5 3M Recent Developments/Updates
6.6 Chiesi
6.6.1 Chiesi Company Information
6.6.2 Chiesi Description and Business Overview
6.6.3 Chiesi Single Dose Dry Powder Inhaler Device Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Chiesi Single Dose Dry Powder Inhaler Device Product Portfolio
6.6.5 Chiesi Recent Developments/Updates
6.7 Teva
6.7.1 Teva Company Information
6.7.2 Teva Description and Business Overview
6.7.3 Teva Single Dose Dry Powder Inhaler Device Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Teva Single Dose Dry Powder Inhaler Device Product Portfolio
6.7.5 Teva Recent Developments/Updates
6.8 Vectura
6.8.1 Vectura Company Information
6.8.2 Vectura Description and Business Overview
6.8.3 Vectura Single Dose Dry Powder Inhaler Device Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Vectura Single Dose Dry Powder Inhaler Device Product Portfolio
6.8.5 Vectura Recent Developments/Updates
6.9 Mannkind
6.9.1 Mannkind Company Information
6.9.2 Mannkind Description and Business Overview
6.9.3 Mannkind Single Dose Dry Powder Inhaler Device Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Mannkind Single Dose Dry Powder Inhaler Device Product Portfolio
6.9.5 Mannkind Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Single Dose Dry Powder Inhaler Device Industry Chain Analysis
7.2 Single Dose Dry Powder Inhaler Device Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Single Dose Dry Powder Inhaler Device Production Mode & Process Analysis
7.4 Single Dose Dry Powder Inhaler Device Sales and 麻豆原创ing
7.4.1 Single Dose Dry Powder Inhaler Device Sales Channels
7.4.2 Single Dose Dry Powder Inhaler Device Distributors
7.5 Single Dose Dry Powder Inhaler Device Customer Analysis
8 Single Dose Dry Powder Inhaler Device 麻豆原创 Dynamics
8.1 Single Dose Dry Powder Inhaler Device Industry Trends
8.2 Single Dose Dry Powder Inhaler Device 麻豆原创 Drivers
8.3 Single Dose Dry Powder Inhaler Device 麻豆原创 Challenges
8.4 Single Dose Dry Powder Inhaler Device 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Hovione
GlaxoSmithKline
AstraZeneca
Novartis
3M
Chiesi
Teva
Vectura
Mannkind

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.